Advisers

Scientific Advisory Boards​

Arquer Diagnostics is supported by internationally recognised clinical advisors across a number of specialist clinical areas. These advisory boards:

Strategically guide our research programmes
Guide preparation and implementation of our clinical studies
Support dissemination of our clinical information

Bladder Cancer Europe Medical Advisory Board

Tim Dudderidge is a consultant urological surgeon and lead of prostate cancer surgical trials at University Hospital Southampton. Tim specialises in prostate cancer and is one of a handful of clinicians combining an interest in imaging and precision diagnostics with skills in both focal therapy and robotic surgery for prostate cancer.

He qualified in 1998 and later gained Doctorate of Medicine MD at the University of Bristol in 2014. He trained in London and spent time undertaking research at University College London gaining an MSc degree. He went through urological training at all the leading cancer centres including Kings College Hospital, University College Hospital, Imperial Healthcare and the Royal Marsden Hospital where he also worked as a consultant. Tim was awarded a Royal College of Surgeons Uro-Oncology Fellowship at Imperial in 2009 and subsequently was the UK’s First Robotic Surgery Fellow at Royal Marsden Hospital.

Tim has research interests in urine-based cancer diagnosis and surgical trials for prostate cancer. He has been principal investigator for all the prostate diagnosis and focal therapy trials in Southampton and collaborated with colleagues as a founder member of the UK focal therapy users’ group.

Paolo Gontero holds the position of Full Professor of Urology at the University of Torino School of Medicine and Chairman of the Division of Urology, San Giovanni Battista Hospital (Molinette), Torino, Italy.

His main clinical interests are in the field of Surgical Uro-Oncology, devoted to Robotic and Laparoscopic oncological surgery of bladder, prostate and kidney cancers. He has strong expertise in minimally invasive live donor nephrectomy and reconstructive surgery of transplanted kidney.

He has authored and co-authored more than 350 publications in international journals (main interest in non-muscle invasive bladder cancer and prostate cancer). He is involved in international trials and working groups on the development of new diagnostic and therapeutic modalities for bladder and prostate cancer. He is a panel member of the European Guidelines for non-muscle invasive bladder cancer.

Stuart McCracken is a Consultant Urological Surgeon and Clinical Director at Sunderland Royal Hospital. He is also a Senior Lecturer at Newcastle University. His clinical specialist interests lie in bladder and prostate cancer diagnostics and treatment, all stone surgeries and all aspects of general urology. He remains very active in the field of bladder and prostate cancer research, with his own research team at Newcastle University, and recently sat on the Executive Board of the Academic Section of the British Association of Urological Surgeons.

Emanuele Montanari is a full Professor of Urology at University of Milan as well as M.D. Urologist Fellow of European Board of Urology. He is currently chief of the Urological Dept. Fondazione Ca Granda-Ospedale Maggiore Policlinico di Milano (Teaching Hospital). In his long and distinguished career, he was President of the European Board of Urology (2010-12) and Member of the Board of the Urolithiasis section of European Society of Urology (eULIS). He is currently Chair of Specialty School of Urology University of Milan and he is very active in research with a particular focus on Endourology and Stones.

Joan Palou Redorta, MD, PhD, is Professor of Urology at the Universitat Autónoma de Barcelona, Spain and Chairman of Urology Department at the famous Fundació Puigvert in Barcelona, dedicated to Uro-oncology for more than 20 years. He is a world-renowned expert in bladder cancer. He is an expert in laparoscopy and robotic surgery belonging to a cooperative group in robotic radical cystectomy. He has been involved in writing the EAU Guidelines for non-muscle invasive bladder cancer and upper urinary tract tumours and published many chapters in medical and urology books as well as published more than 250 articles in peer-reviewed journals (h-index 61). Among many others, he is a member of the Spanish Urological Association, European Association of Urology (EAU), American Urological Association and Société International d’Urologie. He is involved in the organisation of many educational activities and responsible of the Education of urologists in Europe as a Director of the European School of Urology. He participates in International congresses, courses and symposia, as well as being investigator in many national and international clinical trials.

Morgan Rouprêt is currently full Professor (academic position) at AP-HP Sorbonne University, in the Academic Urology Department of the Pitié-Salpêtrière Hospital, in Paris, France.  He is particularly involved in the field of onco-urology and practices minimally invasive surgery and robot-assisted laparoscopic procedures. From 2019, he has been appointed as chairman of the European Section of Onco-Urology (ESOU) of the EAU. Prof. Rouprêt has a PhD in the field of onco-urology and genetic markers. He is a committed researcher and writer (i.e., over 740 so far) in international, peer-reviewed journals. He focuses and writes on urological cancers particularly upper urinary tract tumours and prostate cancer. In addition, he is the main author or co-author of several books for medical students dedicated to education in the field of urology. He is also member of the Editorial Board of the World Journal of Urology.

Fred Witjes is professor in oncological urology at the Radboud University, Nijmegen, Netherlands. His work focuses on translational and clinical research in bladder, prostate and testicular cancer.  He is a member of several international societies, and he chairs, amongst others, the Dutch guidelines committee on bladder cancer and the EAU guidelines committee on metastatic and muscle-invasive bladder cancer. He is reviewer for many, and editor of several urological and oncological journals, including BJUI. He is active participant and leader of many studies with over 550 (peer reviewed) publications, reviews and book chapters.

Bladder Cancer USA Medical Advisory Board

Ashish M. Kamat is a Professor (Tenure) of Urology and Director of Urologic Oncology Fellowship at MD Anderson Cancer Center, and a graduate of the AUA Leadership Program. His expertise is in multidisciplinary management of urologic cancers with an emphasis on bladder and prostate cancer, organ sparing therapies, minimally invasive techniques, and orthotopic bladder substitution (neobladder). He maintains an active research portfolio in particular in identifying predictors of response to therapy – especially immunotherapy – as a first step towards personalised cancer therapeutics. A major focus of his laboratory research is to develop novel treatments for bladder cancer and identify resistance mechanisms and ways to overcome them. He serves as project PI on the MD Anderson Cancer Center GU (Bladder) SPORE. He has authored over 200 publications, editorials & book chapters in prestigious journals; currently co President of the International Bladder Cancer Network, Chair of the Bladder Cancer Task Force for SITC he serves on the board of regional and national societies for Urology.

Janet Kukreja is an Assistant Professor, Urologic Oncologist at University of Colorado Anschutz Medical Campus. She has particular interest in the treatment of urologic cancers including bladder, prostate, kidney, testicular, penile and ureteral cancers. She is a member of many national and international societies, including the International Bladder Cancer Network and the National Society of Women in Urology. She is a reviewer for Journal of Urology and BJU International, editorial board member of Journal of Urology and consulting editor of British Journal of Urology International Compass.

Roger Li is a genitourinary oncologist whose clinical practice focuses on the surgical treatment of bladder, prostate, and kidney cancers. Prior to joining Moffitt, he completed advanced urologic oncology training at MD Anderson Cancer Center in Houston, Texas. His research interest includes the genomic characterisation of genitourinary malignancies in attempt to tailor therapy specific to the patient, as well as the development of novel immunotherapeutic strategies in treating early-stage bladder cancer. His work has previously been highlighted in several national and international urology meetings. He has authored numerous peer reviewed manuscripts and book chapters on urologic oncology.  In addition, he serves as reviewer for many international urologic journals, including British Journal of Urology International, European Urology Oncology, Journal of Clinical Genitourinary Cancer, and BMC Cancer.

Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Her research focuses mainly on the diagnosis and management of urothelial carcinoma. In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalised medicine to patients with bladder cancer. She is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology.

Dr Debasish Sundi is Assistant Professor, Department of Urology, at The Ohio State University Medical Center, James Cancer Hospital and Solove Research Institute. He is also a member of the Translational Therapeutics Program and Pelotonia Institute of Immuno-Oncology at the OSU Comprehensive Cancer Center, focusing on exploring the functions of immune cells in the bladder cancer tumor microenvironment. In addition to performing research, which has been published in numerous peer-reviewed journals, he serves as an editor for BMC Cancer and a reviewer for European Urology, Urologic Oncology, Journal of Urology, Cellular Immunology, PLoS ONE, and JAMA.

Endometrial Cancer Global Medical Advisory Board

Richard Edmondson qualified in medicine from Newcastle University in 1992 and after a year of surgical training in New Zealand undertook speciality training in the Northern Deanery in Obstetrics and Gynaecology with subspecialty training in Gynaecological Oncology at the Queen Elizabeth Hospital, Gateshead. He was awarded an MD from Newcastle University in 2002 for his work investigating the biology of the ovarian surface epithelium which led to his interest in ovarian/gynaecological cancers.

He was appointed as a consultant in Gateshead and honorary senior lecturer in Newcastle in 2005 and in January 2014 he took up the chair of Gynaecological Oncology at the University of Manchester.

His research focuses on developing personalised treatments for patients with advanced gynaecological cancers. In addition to developing personalised treatment algorithms to predict outcomes to surgery he leads a translational programme of research using ex vivo modelling of ovarian cancer to investigate how the DNA damage response can be used to develop potential therapeutic biomarkers. His group has developed techniques to establish real time models for ex vivo testing of drug sensitivity alongside functional assessment of the tumour and this has led to exciting developments in the ability to predict response to novel agents including PARP inhibitors as well as conventional chemotherapy agents such as carboplatin.

Camille Gunderson, M.D., M.S. is an Assistant Professor in the Section of Gynaecologic Oncology, Department of Obstetrics and Gynaecology at Stephenson Cancer Center at the University of Oklahoma Health Sciences Center (OUHSC). She was a member of the National Cancer Institute Project Team Member Application in 2019 and worked with a multidisciplinary team of experts to develop a clinical trial for the newly NCI supported drug abemaciclib.

She received the Gynaecologic Oncology Group Foundation/Foundation for Women’s Cancer New Investigator Award and was appointed to the NRG New Investigator committee and continues serving on the NRG uterine corpus committee. She enjoys teaching physicians in training and received the 2018-2019 Outstanding Faculty Award for Medical Education.

David Mutch is Professor of Obstetrics and Gynaecology, Washington University School of Medicine and Vice-Chair of Gynaecology at the Washington University School of Medicine. He is a member of the Division of Gynaecologic Oncology of the American Board of Obstetrics and Gynaecology and serves as a reviewer for multiple medical journals related to women’s health and cancers of the female reproductive tract. He is the Principal Investigator for NRG Oncology at Washington University and has authored or co-authored over 280 peer-reviewed publications as well as numerous book chapters on the treatment of cancers of the female reproductive tract. He is currently the PI of an endometrial SPORE (Special Project of Research Excellence) grant and serves as the clinical PI on Project 3 which addresses the most efficient and cost-effective way to evaluate individuals for inherited disease. He is the PI of the Integrated Translational Genoproteomics Center at Washington University under a U10 grant. He is a past president of the Society of Gynaecologic Oncology and serves as a member of the FIGO gynaecologic oncologic committee and is the co-Chair for the AJCC committee for gynaecologic oncology. He has been on both the NCI Uterine Steering committee and the NCI Gynaecologic Steering committee.

Alexandre Olawaiye is the director of gynaecologic cancer research at Magee-Women’s hospital of the University of Pittsburgh Medical Center.  He is also the Gynaecologic Oncology Group Foundation principal investigator for the University of Pittsburgh Cancer Institute and in this role has collaborated with multiple clinical scientists across the country to conduct phases I, II and III studies. He has overseen multiple clinical research projects and also studies chemotherapeutic agents and their complications. He is a renowned national and international standard setter in gynaecologic oncology who enjoys mentoring many younger clinicians.  

Denis Querleu is currently Visiting Professor at the University Sacro Cuore, Gemelli Hospital, Rome, Italy and Adjunct Professor at the University of Strasbourg, France of Obstetric, Gynaecology and Oncology. In his long and distinguished career, he has held many senior clinical management positions both in France and Canada. He has authored more than 380 papers referenced in Pubmed on gynaecological cancers and written several surgical textbooks. He has chaired the Guidelines and Quality Assurance Committee of the European Society of Gynaecologic Oncology and has served as President of ESGO from 2017 to 2019. He is currently immediate past president of the ESGO.  A pioneer in advanced laparoscopic surgery for gynaecological cancer he has been involved in teaching and training fellows and attending staff in 26 countries around the world, as well as collaborating in training members of leading institutions, such as the Mayo Clinic and Memorial Sloan-Kettering Cancer Center. He has been the editor in chief of the ESGO e-academy, a web portal for education and continuous medical education in gynaecologic oncology, including global free access to major documents. He is a volunteer at Médecins sans Frontières (Doctors without Borders) for an action on teaching of cervical cancer surgery in Malawi.

Prostate Cancer Europe Medical Advisory Board

Maurizio Brausi is past Chairman of Urology AUSL Modena Ospedale Ramazzini Carpi, Italy and is the Scientific Coordinator at the Hesperia Hospital Modena. He published more than 300 articles in peer reviewed journals and cooperated in writing 7 books on onco-urology (5 on bladder cancer and 2 on prostate cancer). Former Chairman ESUO, he is currently executive Board Member of the Italian College of Surgeons, member of the Scientific Committee SIU (International Society of Urology), member of the Scientific Committee of ESMO (European Society of Medical Oncology) and a reviewer for the Journal of Urology. Additionally, he is investigator of numerous clinical trials and organised numerous national and international symposiums related to uro-oncology. He was the President of the Italian Society of Urology (SIU) in 2015-2016.

Tim Dudderidge is a consultant urological surgeon and lead of prostate cancer surgical trials at University Hospital Southampton. Tim specialises in prostate cancer and is one of a handful of clinicians combining an interest in imaging and precision diagnostics with skills in both focal therapy and robotic surgery for prostate cancer.

He qualified in 1998 and later gained Doctorate of Medicine MD at the University of Bristol in 2014. He trained in London and spent time undertaking research at University College London gaining an MSc degree. He went through urological training at all the leading cancer centres including Kings College Hospital, University College Hospital, Imperial Healthcare and the Royal Marsden Hospital where he also worked as a consultant. Tim was awarded a Royal College of Surgeons Uro-Oncology Fellowship at Imperial in 2009 and subsequently was the UK’s First Robotic Surgery Fellow at Royal Marsden Hospital.

Tim has research interests in urine-based cancer diagnosis and surgical trials for prostate cancer. He has been principal investigator for all the prostate diagnosis and focal therapy trials in Southampton and collaborated with colleagues as a founder member of the UK focal therapy users’ group.

Stuart McCracken is a Consultant Urological Surgeon and Clinical Director at Sunderland Royal Hospital. He is also a Senior Lecturer at Newcastle University. His clinical specialist interests lie in bladder and prostate cancer diagnostics and treatment, all stone surgeries and all aspects of general urology. He remains very active in the field of bladder and prostate cancer research, with his own research team at Newcastle University, and recently sat on the Executive Board of the Academic Section of the British Association of Urological Surgeons.

Arnulf Stenzl is Director of the Department of Urology, University of Tubingen Medical School. He is author or co-author on more than 700 publications and scientific papers in peer reviewed journals and is a member of numerous public and privately initiated steering committees and advisory boards. He holds two international patents.  He has been Chairman of the Scientific Congress Office of the European Association of Urology since 2012 and is now Adjunct Secretary General and Board Member of EAU. He is a member of various national and international urological associations and is on the Editorial Board of the Journal of Urology, European Journal of Urology, Nature Reviews Urology, Scandinavian Journal of Urology and Chinese Journal of Urology. He is president of the German Association of Urology.  His major research interests are bladder and prostate cancer and reconstructive Urology.  Additionally, he is an investigator on numerous clinical trials and has organised many national and international symposiums related to uro-oncology.